Engineering Processing Properties of Acetaminophen by Cosolvent Screening - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Engineering Processing Properties of Acetaminophen by Cosolvent Screening
The authors used common solvents to develop an initial solvent-screening method for laboratory-scale research to determine the solubility, polymorphism, and crystal properties of various active ingredients.


Pharmaceutical Technology
Volume 34, Issue 8, pp. 61-68

9. T. Lee and M.S. Lin, Cryst. Growth Des. 7 (9), 1803–1810 (2007).

10. T. Lee and S.T. Hung, Pharm. Technol. 32 (1), 76–95 (2008).

11. T. Lee, S.T. Hung, and C.S. Kuo, Pharm. Res. 23 (11), 2542–2555 (2006).

12. J.C. Burley et al., Eur. J. Pharm. Sci. 31 (5), 271–276 (2007).

13. N. Al-Zoubi, K. Kachrimanis, and S. Malamataris, Eur. J. Pharm. Sci. 17 (1–2), 13–21 (2002).

14. N. Al-Zoubi and S. Malamataris, Int. J. Pharm., 260 (1), 123–135 (2003).

15. P. Di Martino et al., J. Therm. Anal. 48 (3), 447–458 (1997).

16. M. L. Ramos, J.F. Tyson, and D.J. Curran, Anal. Chim. Acta 364 (1–3), 107–116 (1998).

17. R.G. Hollenbeck, J. Pharm. Sci. 69 (10), 1241–1242 (1980).

18. J.W. Mullin, "Solutions and Solubility," in Crystallization, (Butterworth Heinemann, Oxford, UK, 3rd ed., 1992), pp. 93–94.

19. S.H. Yalkowsky, "Solubilization by Cosolvents," in Solubility and Solubilization in Aqueous Media, (American Chemical Society and Oxford University Press, New York, 1999), pp. 180–235.

20. P.W.S. Heng and L.W. Chan, "Drug Substance and Excipient Characterization," in Handbook of Pharmaceutical Granulation Technology, D. M. Parikh, Ed. (Marcel Dekker, New York, 1st ed., 1997), p. 28.

21. M. Kitamura, M. Sugimoto, J. Cryst. Growth 257 (1–2), 177–184 (2003).

22. M. Lahav and L. Leiserowitz, Chem. Eng. Sci. 56 (7), 2245–2253 (2001).

23. B.F. Ruth, Ind. Eng. Chem. Res. 38 (6), 564–571 (1946).

24. E.W. Comings and T.K. Sherwood, Ind. Eng. Chem. Res. 26 (10), 1096–1098 (1934).

25. K. Miyanami, "Mixing," in Powder Technology Handbook, K. Gotoh, H. Masuda, and K. Higashitani, Eds. (Marcel Dekker, New York, 2nd ed., 1997), p. 618.

26. K. Umeya and I. Sekiguchi, J. Soc. Mater. Sci. Japan. 24 (262), 664–668 (1975).

27. B.E. Kurtz and A.J. Barduhn, Chem. Eng. Prog. 56 (1), 67–72 (1960).

28. T. Lee and C.S. Kuo, Pharm. Technol. 30 (3), 110–120 (2006).

29. W. Nernst, Z. Physik. Chem. 47 (1), 52–55 (1904).

30. E. Brunner, Z. Physik. Chem. 47 (1), 56–102 (1904).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here